Research today. Impact tomorrow.

25% Off the entire catalogue →

Same standards. Greater possibilities.

Research Use Only18+Not for Human ConsumptionReconstitution Materials Not Supplied
Peptide Database

Skin & dermatology research

Melanotan I (MT-I): Research Overview

Melanocortin receptor agonist approved as an implant for a rare light-sensitivity disorder.

Also known as afamelanotide · SCENESSE · MT-I

Research use onlyStrongest evidence: study type not statedReviewed
View product →DatabaseReferences

What is Melanotan I?

Synthetic analog of α-MSH that selectively targets MC1 receptors for melanin stimulation. FDA-approved as SCENESSE implant for erythropoietic protoporphyria (EPP). Research-grade injectable form enables flexible dosing versus the implant version.

What is Melanotan I researched for?

  • Stimulates melanin for deeper, longer-lasting tans with reduced UV requirements
  • Increased melanin density provides natural UV protection and reduces sunburn
  • Promotes uniform melanin distribution minimizing patchy tanning
  • FDA-approved indication for SCENESSE implant

How does Melanotan I work?

Subcutaneous injection delivers peptide directly into systemic circulation. Selectively activates MC1R receptors to stimulate melanin production. Short half-life of approximately 30 minutes necessitates multiple daily dosing for sustained effect.

Reported targets: MC1R

References

  1. MT-I Photoprotection Study PubMed

    2004

    Demonstrated significant photoprotection effects

  2. Melanocortin Receptor Binding Study PubMed

    1997

    Characterized MC1R selectivity

  3. Pharmacokinetics Injectable MT-I PubMed

    1997

    Established half-life and bioavailability parameters

  4. This information is for educational and research purposes only. Consult a healthcare professional before use.

  5. A comprehensive research database for peptides, therapies, and protocols. Information provided for educational purposes only.

  6. © 2026 Peptide Database. For educational and research purposes only.

  7. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours

    Mollenhauer J, Wiemann S, Scheurlen W, et al. · Nature genetics · 1997

    PMID 9288095

  8. Polyadenylation of telomerase RNA in budding yeast

    Chapon C, Cech TR, Zaug AJ · RNA (New York, N.Y.) · 1997

    PMID 9409624

  9. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers

    Dorr RT, Ertl G, Levine N, et al. · Archives of dermatology · 2004

    PMID 15262693